Search results for "Neoplastic"

showing 10 items of 2901 documents

Reactivity of antitumor coinage metal-based N-heterocyclic carbene complexes with cysteine and selenocysteine protein sites

2021

Abstract The reaction of the antitumor M(I)-bis-N-heterocyclic carbene (M(I)-NHC) complexes, M = Cu, Ag, and Au, with their potential protein binding sites, i.e. cysteine and selenocysteine, was investigated by means of density functional theory approaches. Capped cysteine and selenocysteine were employed to better model the corresponding residues environment within peptide structures. By assuming the neutral or deprotonated form of the side chains of these amino acids and by considering the possible assistance of an external proton donor such as an adjacent acidic residue or the acidic component of the surrounding buffer environment, we devised five possible routes leading to the binding o…

SilverAnticancer; Copper(I) complexes; DFT calculations; Gold(I) complexes; N-heterocyclic carbenes; Silver(I) complexesStereochemistryCoinage metalsAntineoplastic AgentsProtonationLigandsDFT calculationsBiochemistrySilver(I) complexesInorganic Chemistrychemistry.chemical_compoundDeprotonationProtein structureCoordination ComplexesCysteineN-heterocyclic carbenesDensity Functional Theorychemistry.chemical_classificationMolecular StructureSelenocysteineCopper(I) complexesSelenocysteineAmino acidAnticancerGold(I) complexesModels ChemicalchemistryThermodynamicsGoldCarbeneCopperCysteineJournal of Inorganic Biochemistry
researchProduct

New combinations for mantle cell lymphoma: concerted action needed.

2011

Sirolimusbusiness.industryLymphoma Mantle-Cellmedicine.diseaseArticleAntibodies Monoclonal Murine-DerivedOncologyAction (philosophy)Antineoplastic Combined Chemotherapy ProtocolsCancer researchMedicineHumansMantle cell lymphomabusinessRituximabThe Lancet. Oncology
researchProduct

Transcriptomic identification of miR-205 target genes potentially involved in metastasis and survival of cutaneous malignant melanoma

2020

AbstractCutaneous melanoma is an aggressive neoplasm and is responsible for the majority of skin cancer deaths. Several miRNAs are involved in melanoma tumor progression. One of them is miR-205, the loss of which contributes to the development of melanoma metastasis. We evaluated whole-genome mRNA expression profiling associated with different miR-205 expression levels in melanoma cells. Differential expression analysis identified 243 differentially expressed transcripts including inositol polyphosphate 5′-phosphatase-like protein-1 (INPPL1) and BTB/POZ Domain-Containing Protein 3 (BTBD3). INPPL1 and BTBD3 were downregulated when melanoma cells expressed miR-205, indicating that these genes…

Skin NeoplasmsDown-Regulationlcsh:MedicineNerve Tissue ProteinsBiologyArticleDisease-Free SurvivalMetastasisTranscriptomeCancer epigeneticsmicroRNATumor Cells CulturedmedicineHumansNeoplasm MetastasisCàncerlcsh:Science3' Untranslated RegionsMelanomaLymph nodeMultidisciplinaryGene Expression ProfilingMelanomalcsh:Rmedicine.diseaseGene Expression Regulation NeoplasticMicroRNAsmedicine.anatomical_structureTumor progressionLymphatic MetastasisPhosphatidylinositol-345-Trisphosphate 5-PhosphatasesCutaneous melanomaCancer researchlcsh:QSkin cancerTranscriptomeScientific Reports
researchProduct

Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma – an update

2020

CTLA-4 and PD-1 play a key role in tumor-induced downregulation of lymphocytic immune responses. Immune checkpoint inhibitors have been shown to alter the immune response to various cancer types. Anti-CTLA-4 and anti-PD-1 antibodies affect the interaction between tumor, antigen-presenting cells and T lymphocytes. Clinical studies of the anti-CTLA-4 antibody ipilimumab and the anti-PD-1 antibodies nivolumab and pembrolizumab have provided evidence of their positive effects on overall survival in melanoma patients. Combined treatment using ipilimumab and nivolumab has been shown to achieve five-year survival rates of 52 %. Such enhancement of the immune response is inevitably associated with …

Skin NeoplasmsDrug-Related Side Effects and Adverse ReactionsSide effectProgrammed Cell Death 1 ReceptorMedizinIpilimumabDermatologyPembrolizumabAntibodies Monoclonal Humanized030207 dermatology & venereal diseases03 medical and health sciencesAntineoplastic Agents Immunological0302 clinical medicineImmune systemmedicineHumansCTLA-4 AntigenImmune Checkpoint InhibitorsMelanomabusiness.industryMelanomamedicine.diseaseCombined Modality TherapyIpilimumabImmune checkpoint3. Good healthNivolumabCTLA-4ImmunologyImmunotherapyNivolumabbusinessmedicine.drug
researchProduct

Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth.

2013

International audience; Dacarbazine (DTIC) is a cytotoxic drug widely used for melanoma treatment. However, the putative contribution of anticancer immune responses in the efficacy of DTIC has not been evaluated. By testing how DTIC affects host immune responses to cancer in a mouse model of melanoma, we unexpectedly found that both natural killer (NK) and CD8(+) T cells were indispensable for DTIC therapeutic effect. Although DTIC did not directly affect immune cells, it triggered the upregulation of NKG2D ligands on tumor cells, leading to NK cell activation and IFNγ secretion in mice and humans. NK cell-derived IFNγ subsequently favored upregulation of major histocompatibility complex cl…

Skin NeoplasmsMelanoma ExperimentalCD8-Positive T-LymphocytesPharmacologyMESH: Antineoplastic Agents AlkylatingLigandsBiochemistryMiceInterleukin 210302 clinical medicineMESH: Up-RegulationMESH: LigandsCytotoxic T cell[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyMESH: AnimalsMESH : Up-RegulationMESH : LigandsMESH : Melanoma ExperimentalMelanomaMESH : Mice NudeMESH : CD8-Positive T-LymphocytesMESH: CD8-Positive T-LymphocytesUp-Regulation3. Good healthDacarbazineKiller Cells NaturalMESH: Melanoma ExperimentalNK Cell Lectin-Like Receptor Subfamily K030220 oncology & carcinogenesisMESH: NK Cell Lectin-Like Receptor Subfamily K[SDV.IMM]Life Sciences [q-bio]/ImmunologyMESH : Killer Cells Naturalmedicine.drugMESH: Killer Cells NaturalMESH: Cell Line Tumor[SDV.IMM] Life Sciences [q-bio]/ImmunologyMESH: Interferon-gammaDacarbazineMESH : Antineoplastic Agents AlkylatingMice NudeMESH : Mice Inbred C57BLDermatologyBiologyMajor histocompatibility complexMESH: DacarbazineInterferon-gamma03 medical and health sciencesImmune systemDownregulation and upregulationMESH: Mice Inbred C57BLCell Line TumorMESH : MicemedicineMESH : NK Cell Lectin-Like Receptor Subfamily KMESH: Mice NudeAnimalsHumansMESH : DacarbazineAntineoplastic Agents AlkylatingMolecular BiologyMESH: MiceMESH : Interferon-gammaMESH: HumansMESH : Cell Line TumorMESH: Skin NeoplasmsMESH : Skin NeoplasmsMESH : HumansCell Biologymedicine.diseaseMESH : Disease Models AnimalMice Inbred C57BLDisease Models Animalbiology.proteinMESH : AnimalsMESH: Disease Models AnimalCD8030215 immunology
researchProduct

Biological tolerance of different materials in bulk and nanoparticulate form in a rat model: sarcoma development by nanoparticles

2006

In order to study the pathobiological impact of the nanometre-scale of materials, we evaluated the effects of five different materials as nanoparticulate biomaterials in comparison with bulk samples in contact with living tissues. Five groups out of 10 rats were implanted bilaterally for up to 12 months with materials of the same type, namely TiO 2 , SiO 2 , Ni, Co and polyvinyl chloride (PVC), subcutaneously with bulk material on one side of the vertebral column and intramuscularly with nanoparticulate material on the contralateral side. At the end of each implantation time, the site was macroscopically examined, followed by histological processing according to standard techniques. Malign…

Skin NeoplasmsSilicon dioxideBiological; tolerance; different; materials; bulk; nanoparticulate; rat model; sarcoma; development; nanoparticlesRat modelBiomedical EngineeringBiophysicsNanoparticleMetal NanoparticlesBioengineeringBiocompatible MaterialsBiochemistryPreneoplastic lesionBiomaterialschemistry.chemical_compoundNickelBulk samplesMaterials TestingmedicineAnimalsPolyvinyl ChlorideTitaniumSarcomaCobaltmedicine.diseaseSilicon DioxideRatsPolyvinyl chloridechemistrySarcomaImplantation timeBiotechnologyBiomedical engineeringResearch Article
researchProduct

UV Exposure Boosts Transcutaneous Immunization and Improves Tumor Immunity: Cytotoxic T-Cell Priming through the Skin

2010

Immunologic approaches to combat cancer aim at the induction of tumor-reactive immune responses to achieve long-term protection. In this context, we recently developed a transcutaneous immunization (TCI) method using the Toll-like receptor (TLR) 7 agonist imiquimod and a peptide epitope. Application onto intact skin induces potent cytotoxic T lymphocyte (CTL) responses and protection against transplanted tumors. The purpose of this study was to explore the effects of UV irradiation on imiquimod-based TCI. Here we show that skin exposure to low-dose UV light before TCI with imiquimod strongly boosts specific CTL responses leading to memory formation and enhanced tumor protection. Toward the …

Skin NeoplasmsUltraviolet RaysPriming (immunology)ImiquimodAntineoplastic AgentsDermatologyBiochemistryEpitopeMiceImmune systemImmune ToleranceCytotoxic T cellMedicineAnimalsReceptorMolecular BiologySkinImiquimodMembrane GlycoproteinsDose-Response Relationship Drugbusiness.industryDose-Response Relationship RadiationCell BiologyMice Mutant StrainsVaccinationMice Inbred C57BLCTL*Toll-Like Receptor 7Langerhans CellsImmunologyAminoquinolinesbusinessImmunologic Memorymedicine.drugT-Lymphocytes CytotoxicJournal of Investigative Dermatology
researchProduct

The mitotic kinase Aurora-A promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERα+ breast cancer cells

2013

In this study, we demonstrate that constitutive activation of Raf-1 oncogenic signaling induces stabilization and accumulation of Aurora-A mitotic kinase that ultimately drives the transition from an epithelial to a highly invasive mesenchymal phenotype in estrogen receptor α-positive (ERα(+)) breast cancer cells. The transition from an epithelial- to a mesenchymal-like phenotype was characterized by reduced expression of ERα, HER-2/Neu overexpression and loss of CD24 surface receptor (CD24(-/low)). Importantly, expression of key epithelial-to-mesenchymal transition (EMT) markers and upregulation of the stemness gene SOX2 was linked to acquisition of stem cell-like properties such as the ab…

Smad5 ProteinCancer ResearchEpithelial-Mesenchymal TransitionMAP Kinase Signaling SystemReceptor ErbB-2Active Transport Cell NucleusEstrogen receptorMice NudeBreast NeoplasmsBiologyArticleMicebreast cancerSOX2Cell MovementCell Line TumorGeneticsAnimalsHumansEpithelial–mesenchymal transitionKinase activityNeoplasm MetastasisPhosphorylationRNA Small InterferingMolecular BiologyAurora Kinase Ametastases mitosisSOXB1 Transcription FactorsEstrogen Receptor alphaCD24 AntigenXenograft Model Antitumor AssaysstemneGene Expression Regulation NeoplasticProto-Oncogene Proteins c-rafSettore BIO/18 - GeneticaTumor progressionembryonic structuresCancer researchMCF-7 CellsNeoplastic Stem CellsProto-Oncogene Proteins c-rafFemaleRNA InterferenceSignal transductionEstrogen receptor alphaNeoplasm Transplantation
researchProduct

The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies

2021

The term liquid biopsy (LB) refers to the use of various biological fluids as a surrogate for neoplastic tissue to achieve information for diagnostic, prognostic and predictive purposes. In the current clinical practice, LB is used for the identification of driver mutations in circulating tumor DNA derived from both tumor tissue and circulating neoplastic cells. As suggested by a growing body of evidence, however, there are several clinical settings where biological samples other than tissue could be used in the routine practice to identify potentially predictive biomarkers of either response or resistance to targeted treatments. New applications are emerging as useful clinical tools, and o…

Societies ScientificCancer ResearchContext (language use)ReviewNeoplastic CellsBioinformaticsCirculating tumor cellCirculatingBiomarkers TumorMedicineHumansDigital polymerase chain reactionLiquid biopsycfDNAcirculating tumor DNAcfDNA; circulating cell-free DNA; circulating tumor DNA; ctDNA; digital PCR; liquid biopsy; next-generation sequencing; real-time PCRTumorCirculating Neoplastic Cellsliquid biopsybusiness.industrydigital PCRScientificctDNAcirculating cell-free DNANeoplastic Cells CirculatingCirculating Cell-Free DNAcfDNA; circulating cell-free DNA; circulating tumor DNA; ctDNA; digital PCR; liquid biopsy; next-generation sequencing; real-time PCR; Biomarkers Tumor; Humans; Italy; Liquid Biopsy; Neoplastic Cells Circulating; Societies ScientificOncologyItalyCirculating tumor DNAPosition papernext-generation sequencingSocietiesbusinessreal-time PCRBiomarkersHuman
researchProduct

Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment.

2010

<i>Objective:</i> To evaluate the safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma (HCC) after progression under sorafenib treatment. <i>Methods:</i> Sunitinib was administered at 37.5 mg daily (4-weeks-on/2-weeks-off schedule) after progression under sorafenib treatment. Adverse events (AEs) were assessed using NCI-CTCAE v3.0, and tumor response was evaluated according to RECIST. Data were analyzed retrospectively. <i>Results:</i> Eleven patients with metastatic disease were treated. Seven patients (64%) presented with no liver cirrhosis, including 3 patients with a history of liver transplantation. The first radiologic…

SorafenibAdultMaleNiacinamideCancer Researchmedicine.medical_specialtyCirrhosisCarcinoma HepatocellularIndolesPyridinesmedicine.medical_treatmentAntineoplastic AgentsLiver transplantationGastroenterologySeverity of Illness IndexDrug Administration ScheduleInternal medicinemedicineSunitinibHumansPyrrolesTreatment FailureAgedRetrospective StudiesSunitinibbusiness.industryPhenylurea CompoundsBenzenesulfonatesLiver NeoplasmsGeneral MedicineMiddle AgedSorafenibmedicine.diseasedigestive system diseasesSurgeryRadiographyTreatment OutcomeOncologyTumor progressionDrug Resistance NeoplasmHepatocellular carcinomaDisease ProgressionFemaleLiver functionLiver cancerbusinessmedicine.drugOncology
researchProduct